Geoffrey R. Oxnard

Also affiliated with Harvard University, Eli Lilly (United States), Dana-Farber Cancer Institute, Foundation Medicine (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Papers

Driven by 23 papers — median percentile 0. Top paper: “Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial”.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800

N/A

3.5DataRank · unranked

140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9507

N/A

1.5DataRank · unranked

39 citations

Daniel B. Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari +13 more

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis

JCO Precision Oncology(2020)10.1200/po.20.00121

N/A

1.5DataRank · unranked

29 citations

Evan W. Clark, Marina S.D. Milan, Christine Champagne, Kesi Michael, Mark M. Awad +10 more

Germline EGFR Mutations and Familial Lung Cancer

Journal of Clinical Oncology(2023)10.1200/jco.23.01372

N/A

1.4DataRank · unranked

60 citations

Ruthia Chen, Jennifer C. Pharr, Diane R. Koeller, Arrien A. Bertram, Suzanne E. Dahlberg +18 more

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations

Clinical Cancer Research(2012)10.1158/1078-0432.ccr-11-2109

N/A

0.885DataRank · unranked

364 citations

Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, William D. Travis +5 more

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3608

N/A

0.811DataRank · unranked

222 citations

Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi +18 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0.724DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1844

N/A

0.564DataRank · unranked

42 citations

Mari Kuraguchi, Man Xu, Andrew Portell, Luke J. Taus, Irmina Diala +17 more

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1493

N/A

0.546DataRank · unranked

37 citations

Julia Wilkerson, Sanja Karovic, Binsheng Zhao, Jessica Flynn, Mengxi Zhou +13 more

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9077

N/A

0.520DataRank · unranked

31 citations

Sumithra J. Mandrekar, Geoffrey R. Oxnard, David Kozono, Shauna L. Hillman, Suzanne E. Dahlberg +13 more

Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

JCO Precision Oncology(2021)10.1200/po.20.00419

N/A

0.510DataRank · unranked

29 citations

Christie J. Lau, Marina S.D. Milan, Julianna Supplee, Jonathan W. Riess, Penelope A. Bradbury +4 more

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100151

N/A

0.241DataRank · unranked

4 citations

Rubii M. Tamen, Pablo Martínez, Alicia Sable-Hunt, Tony Addario, Pete Barbour +11 more

Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3747

N/A

0.208DataRank · unranked

3 citations

Alison M. Urvalek, Minh Ha, Kavita S. Garg, Aimee Bence Lin, Anna M. Szpurka +4 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0098

N/A

0DataRank · unranked

1 citations

Cong Chen, Jin Y. Jin, Scott Van Wart, Sarah K. Martin, Brad A. Davidson +4 more

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100146

N/A

0DataRank · unranked

4 citations

Meng Zhou, Meredith Bemus, Julius Nevin, Anwesha Nag, Ruthia Chen +6 more

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Nature Communications(2022)10.1038/s41467-022-33210-2

N/A

0DataRank · unranked

28 citations

Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin P. Hung +18 more

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy

The Journal of Molecular Diagnostics(2026)10.1016/j.jmoldx.2025.12.004

N/A

0DataRank · unranked

0 citations

Zoe Fleischmann, Smruthy Sivakumar, Radwa Sharaf, Erik A. Williams, Benjamin Kaplan +18 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1

N/A

0DataRank · unranked

0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Data from Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

(2023)10.1158/1078-0432.c.6520155

N/A

0DataRank · unranked

0 citations

Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, André L. Moreira +5 more

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.018

N/A

0DataRank · unranked

5 citations

Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama, Philippe A. Cassier +20 more

Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy

Cancer Research(2020)10.1158/0008-5472.can-20-0134

N/A

0DataRank · unranked

10 citations

Geoffrey R. Oxnard, Cloud P. Paweletz, Lynette M. Sholl

Geoffrey R. Oxnard

Indexed papers

Top data-sharing exemplar

Papers